WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018014098) USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN ERYTHEMA IN PERIORBITAL DARK CIRCLES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/014098    International Application No.:    PCT/BR2017/050123
Publication Date: 25.01.2018 International Filing Date: 19.05.2017
IPC:
A61K 31/498 (2006.01), A61P 17/00 (2006.01)
Applicants: HEXSEL, Doris Maria [BR/BR]; (BR).
DE OLIVEIRA DAL'FORNO DINI, Taciana [BR/BR]; (BR)
Inventors: HEXSEL, Doris Maria; (BR).
DE OLIVEIRA DAL'FORNO DINI, Taciana; (BR)
Agent: LEÃO BARCELLOS, Milton Lucídio; (BR)
Priority Data:
BR102016016722-1 19.07.2016 BR
BR132017006993-0 05.04.2017 BR
Title (EN) USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN ERYTHEMA IN PERIORBITAL DARK CIRCLES
(FR) UTILISATION D’UNE COMPOSITION PHARMACEUTIQUE DESTINÉE AU TRAITEMENT DE L’ÉRYTHÈME CUTANÉ DES CERNES
(PT) USO DE COMPOSIÇÃO FARMACÊUTICA DESTINADA AO TRATAMENTO DE ERITEMA CUTÂNEO DAS OLHEIRAS
Abstract: front page image
(EN)The present invention belongs to the technological field of the cosmetic and pharmaceutical industries and relates, more specifically, to a second use composition developed for treating a specific dermatological condition, the skin erythema in periorbital dark circles. The solution described in the present document relates to the use of a composition containing a substance of the pharmacological group of alpha-adrenergic receptor agonists, such as brimonidine or other drugs of the same pharmacological group. This substance is present in the composition in effective therapeutic quantities for treating the vascular component of the erythema which is generally present in the area of the lower eyelids, known under the common name of dark circles under the eyes. Owing to the vascular component of this condition, when the product is applied to the area of the lower eyelids, a significant decrease in the chronic florid or reddish and/or darkened aspect of this area is observed, because of the vasoconstrictive effect of the product. The composition can thus be also associated with other compounds in order to provide alternatives to change the darkened aspect of this area.
(FR)La présente invention relève du secteur technologie des industries cosmétique et pharmaceutique et concerne plus particulièrement une composition de seconde utilisation destinée au traitement d’une affection dermatologique spécifique, soit l’érythème cutané des cernes. La solution décrite dans le présente document concerne l'utilisation d’une composition contenant une substance du groupe pharmacologique des agonistes des récepteurs alpha-adrénergiques, tels que la brimonidine ou un autre médicament du même groupe pharmacologique. Cette substance est présente dans la composition en quantités thérapeutiquement efficaces pour traiter la composante vasculaire de l’érythème généralement présent autour des paupières inférieures, que l'on appelle communément « cernes ». Du fait de la composante vasculaire présente dans cette affection, lors de l’application du produit au voisinage des paupières inférieures, on observe une diminution significative de l’aspect rosé ou rougi et/ou obscurci chronique sur cette région grâce à l’effet vasoconstricteur du produit. Par conséquent, la composition peut également être associée à d’autres composé en vue d’obtenir des solutions alternatives modifiant l’aspect obscurci de cette région.
(PT)A presente invenção pertence ao setor tecnológico das indústrias cosmética e farmacêutica e se refere, mais especificamente, a uma composição de segundo uso desenvolvida ao tratamento de uma condição dermatológica específica que consiste no eritema cutâneo das olheiras. A solução descrita no presente documento refere-se à utilização de uma composição contendo uma substância do grupo farmacológico dos agonistas dos receptores alfa-adrenérgicos, como a brimonidina ou outra droga do mesmo grupo farmacológico. Tal substância está presente na composição em quantidades terapêuticas eficazes para tratar o componente vascular do eritema geralmente presente na região das pálpebras inferiores, comumente denominado de olheiras. Devido ao componente vascular presente nesta condição, a partir da aplicação do produto na região das pálpebras inferiores, observa-se uma diminuição significativa do aspecto rosado ou avermelhado e/ou escurecido crônico na região, devido ao efeito vasoconstritor do produto. Tendo isso em vista, a composição também pode ser associada a outros compostos objetivando atingir alternativas que alterem o aspecto escurecido dessa região
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Portuguese (PT)
Filing Language: Portuguese (PT)